期刊
TARGETED ONCOLOGY
卷 8, 期 3, 页码 183-188出版社
SPRINGER
DOI: 10.1007/s11523-013-0266-9
关键词
NRAS mutation; Colorectal cancer; Bevacizumab; Q61K
类别
资金
- National Center for Research Resources, a component of the NIH Roadmap for Medical Research [RR024148]
Despite development of new therapies, metastatic colorectal cancer (mCRC) largely remains an incurable disease. Approximately 2-6 % of colorectal cancers harbor NRAS mutations. The anti-VEGF antibody bevacizumab is a backbone of most therapeutic regimens; however, biomarkers predicting its activity are not known. We report two cases of mCRC with a Q61K NRAS mutation that had a favorable response to bevacizumab and the histone deacetylase inhibitor valproic acid. In contrast, none of ten patients with wild-type NRAS or unknown NRAS status and mutated KRAS (NRAS and KRAS mutations are mutually exclusive) responded to the same regimen. These results suggest that NRAS mutation merits further investigation as a potential biomarker predicting the efficacy of bevacizumab-based treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据